Suppr超能文献

马拉维若治疗后仍有复制的患者中 HIV-1 的动力学和辅助受体使用情况。

HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.

机构信息

Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, Bordeaux, France.

出版信息

Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3.

Abstract

There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.

摘要

有证据表明,在马拉维若(MVC)的压力下,HIV-1 的进化会导致 X4 嗜性变异体和/或 MVC 耐药的 R5 嗜性分离株的选择。然而,在含有 MVC 的方案中发生病毒学失败(VF)的患者中,HIV-1 变异体的病毒动力学仍研究甚少。在这里,我们使用群体序列和超深度测序研究了与核心受体使用和 MVC 治疗前 HIV-1 准种性质有关的 HIV-1 在 MVC 上的 V3 环进化。大多数患者在基线时没有检测到可检测的少数 X4 变体。对嗜性的进化进行了随访,直到发生 VF,并显示了这些患者中病毒进化的三种可能性:预先存在的 X4 变体的出现,具有 V3 环突变的新选择的 R5 变体,或没有选择已知突变的 R5 变体的复制。

相似文献

1
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3.
3
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.
5
Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Antiviral Res. 2011 Dec;92(3):488-92. doi: 10.1016/j.antiviral.2011.10.003. Epub 2011 Oct 13.
7
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Crit Rev Microbiol. 2015;41(4):473-87. doi: 10.3109/1040841X.2013.867829. Epub 2014 Mar 17.
8
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.
9
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
J Antimicrob Chemother. 2012 Jun;67(6):1479-85. doi: 10.1093/jac/dks055. Epub 2012 Feb 23.

引用本文的文献

1
Dynamic Co-evolution and Interaction of Avian Leukosis Virus Genetic Variants and Host Immune Responses.
Front Microbiol. 2017 Jun 26;8:1168. doi: 10.3389/fmicb.2017.01168. eCollection 2017.
3
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16. Print 2016 Oct.
4
In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.
Front Microbiol. 2016 Feb 9;7:110. doi: 10.3389/fmicb.2016.00110. eCollection 2016.
5
6
Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):437-50. doi: 10.1128/AAC.02285-15. Print 2016 Jan.
8
Deep sequencing: becoming a critical tool in clinical virology.
J Clin Virol. 2014 Sep;61(1):9-19. doi: 10.1016/j.jcv.2014.06.013. Epub 2014 Jun 24.

本文引用的文献

1
Pitfalls of HIV genotypic tropism testing after treatment interruption.
J Antimicrob Chemother. 2013 Jan;68(1):188-9. doi: 10.1093/jac/dks362. Epub 2012 Sep 6.
3
Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism.
Antimicrob Agents Chemother. 2011 Jun;55(6):2831-6. doi: 10.1128/AAC.00091-11. Epub 2011 Apr 4.
5
HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.
J Transl Med. 2011 Jan 27;9 Suppl 1(Suppl 1):S2. doi: 10.1186/1479-5876-9-S1-S2.
8
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage.
J Clin Virol. 2010 Feb;47(2):126-30. doi: 10.1016/j.jcv.2009.11.018. Epub 2009 Dec 16.
10
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Curr Opin HIV AIDS. 2009 Mar;4(2):118-24. doi: 10.1097/COH.0b013e3283223d46.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验